ArticleTranslational cancer research2020
Effects of different treatments and other factors on the prognosis of patients with ewing sarcoma.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEwing sarcoma is a small round cell tumor of bone or soft tissue originating from the neuroectoderm. Aggressive and highly malignant are the main pathological features of the tumor. Studying the effects of different treatments and other factors on prognosis will help us to understand the disease more deeply and find a way to actively deal with it.
methodsThrough the search of the National Cancer Institute database, ewing sarcoma patients registered between January 1, 2004 and December 31, 2015 were selected as research goals. Summarize the basic information of patients included in the study, including demographics, tumor pathology and treatment. Kaplan-Meier survival curves and log-rank test were used to analyze the overall survival (OS) and ewing sarcoma-specific survival (ESSS) of each prognostic factor and categorical variable. Multivariate Cox regression analysis was used to analyze all-cause mortality (ACM) and ewing sarcoma-specific mortality (ESSM) for each prognostic factor and categorical variable.
resultsA total of 837 ewing sarcoma patients were included in this article. Patients receiving chemotherapy (CT), radiotherapy (RT) or surgery were 804 (96.1%), 414 (49.5%), and 524 (62.6%). The mean age and median age of 837 patients were 19.92 and 16 years, respectively. The mortality rate gradually increased with the increase of the age at diagnosis (ACM: 50.6%
conclusionsFrom the demographic and tumor pathology data, the older patients at the age of diagnosis, married, the primary sites in the pelvic bones, sacrum coccyx and associated joints, American Joint Committee on Cancer (AJCC) III-IV, T2-T3, N1 and M1 stage tumors are all prompted to patients' poor prognosis. Compared with CT, CT and RT, or CT and RT and surgery, ewing sarcoma patients receiving CT combined with surgery have the longest median survival, the lowest mortality, and the best prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.